New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For AAPL;JPM;RDSA;NVS;BKS;WDC;GD;VIA;VIAB;BLK;MPC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 >>
August 21, 2015
13:11 EDTVIA, VIABFly Watch: 'Straight Outta Compton' eyes second weekend at top spot
Subscribe for More Information
12:49 EDTAAPLReport: Apple may be working on smart bands for Watch, Apple Insider says
Apple may be working on "smart bands" for the Apple Watch product in order to add more health tracking functions, reports Apple Insider, citing Czech website Letem Svetem Applem. Citing unnamed sources, the Czech website said Apple is planning to announce new bands that will connect the hidden port of the Apple Watch and add functionality to the device. The smart bands could launch as early as 2016. Reference Link
12:43 EDTAAPLJim Chanos says still long Apple, short HP
Subscribe for More Information
10:23 EDTAAPLApple falls, levels to watch
Subscribe for More Information
09:40 EDTWDCWestern Digital Q3 TAM tracking ahead of guidance, says Cleveland Research
Subscribe for More Information
09:34 EDTAAPLActive equity options trading on open
Active equity options trading on open: AAPL FB BAC NFLX DIS TSLA TWTR
08:40 EDTJPMCanadian Security Traders Association to hold a conference
Subscribe for More Information
08:11 EDTAAPLDaimler AG could collaborate with Google, Apple, Reuters says
Subscribe for More Information
06:01 EDTAAPLABI Research: Portable PC sales to remain flat in 2015, DigiTimes says
Subscribe for More Information
05:25 EDTNVSNovartis acquires all remaining rights to Ofatumumab from GSK
Novartis (NVS) announced that it has entered into an agreement to acquire all remaining rights to Ofatumumab from GlaxoSmithKline (GSK). Ofatumumab, a fully human monoclonal antibody which targets CD20, is being developed for relapsing remitting multiple sclerosis, or RRMS, and other autoimmune indications. Novartis previously acquired the rights to Ofatumumab for oncology indications and it is marketed under the brand name Arzerra. Novartis will be responsible for the worldwide development, regulatory and commercialization activities for Ofatumumab. Under the terms of the agreement, Novartis will make an initial upfront payment of $300M to GSK for the acquisition of the compound and a further payment of $200M payable following the start of a phase III study in MS by Novartis. Upon completion of pre-determined milestones, contingent payments of up to $534M may be made. Novartis will also pay royalties of up to 12% to GSK on any future net sales of Ofatumumab in autoimmune conditions.
August 20, 2015
16:00 EDTAAPLOptions Update; August 20, 2015
iPath S&P 500 VIX Short-Term Futures up 1.49 to 17.70. Option volume leaders: AAPL BAC FB NFLX DIS INTC BABA MU
12:24 EDTAAPLVIX methodology for Apple up 12% to 33.29
10:22 EDTAAPLApple falls, levels to watch
Subscribe for More Information
09:36 EDTAAPLActive equity options trading on open
Subscribe for More Information
09:03 EDTJPMJPMorgan appoints General Ray Odierno as senior advisor
JPMorgan Chase & Co. announced the appointment of retired four-star General Raymond T. Odierno, former Chief of Staff of the U.S. Army, to a senior advisory capacity at the firm, effective September 1.
08:45 EDTAAPLApple iPhone 6S may not pressure gross margins, says Bernstein
Subscribe for More Information
06:36 EDTVIAB, VIABernstein cuts Disney, Time Warner with TV entering 'structural decline'
Bernstein analyst Todd Juenger downgraded his rating on both Disney (DIS) and Time Warner (TWX) saying the U.S. television industry is entering a period of "prolonged structural decline." With viewers moving away from ad-supported platforms to non-ad-supported, media companies with the least exposure to U.S. advertising represent the most favorable investments, Juenger tells investors in a 48-page research note on the Media sector. The analyst moved both companies to a Market Perform rating from Outperform, and lowered his price target for Disney to $114 from $125 and for Time Warner to $90 from $101. He called the downgrade of Time Warner a "very close call" as his new price target still represents 15% upside from current levels. Share performance in the entire Media sector will be challenged until the content owners take steps to "reclaim on-demand viewing" from streaming services like Netflix (NFLX) and use it to protect affiliate fees, Juenger argues. His Outperform-rated names are Nielsen (NLSN) and 21st Century Fox (FOXA). Along with Time Warner and Disney, the analyst has Market Perform ratings on AMC Networks (AMCX), CBS (CBS), Scripps Networks (SNI) and Discovery (DISCA). Juenger has an Underperform rating on Viacom (VIAB). Wells Fargo on Tuesday also downgraded Disney to Market Perform. Piper Jaffray this morning told investors that the recent pullback in shares of AMC Networks brings a "great" entry point into the name.
06:13 EDTAAPLApple's Australian bonds raise $1.2B within two hours, SMH reports
Subscribe for More Information
06:07 EDTAAPLApple's 12.9-inch iPad to feature displays from Sharp, DigiTimes reports
Subscribe for More Information
05:29 EDTNVSNovartis Odomzo gains EU approval for laBCC
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use